News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

17,898 Results

Type

Article (3071)
Company Profile (4)
Press Release (14823)

Section

Business (7054)
Career Advice (96)
Deals (990)
Drug Delivery (12)
Drug Development (2650)
Employer Resources (13)
FDA (588)
Job Trends (624)
News (11038)
Policy (1039)

Tag

Date

Today (2)
Last 7 days (9)
Last 30 days (46)
Last 365 days (838)
2024 (839)
2023 (818)
2022 (2045)
2021 (1817)
2020 (1403)
2019 (1200)
2018 (965)
2017 (1221)
2016 (911)
2015 (985)
2014 (735)
2013 (602)
2012 (636)
2011 (611)
2010 (623)

Location

Africa (51)
Asia (1293)
Australia (180)
California (55)
Canada (30)
China (6)
Connecticut (5)
Delaware (5)
Europe (4458)
Indiana (5)
Massachusetts (72)
New Jersey (18)
New York (10)
North Carolina (15)
Northern California (29)
Pennsylvania (9)
South America (51)
Southern California (15)
Texas (6)
Washington State (5)

Filters

Type

Article (3071)
Company Profile (4)
Press Release (14823)

Section

Business (7054)
Career Advice (96)
Deals (990)
Drug Delivery (12)
Drug Development (2650)
Employer Resources (13)
FDA (588)
Job Trends (624)
News (11038)
Policy (1039)

Tag

Date

Today (2)
Last 7 days (9)
Last 30 days (46)
Last 365 days (838)
2024 (839)
2023 (818)
2022 (2045)
2021 (1817)
2020 (1403)
2019 (1200)
2018 (965)
2017 (1221)
2016 (911)
2015 (985)
2014 (735)
2013 (602)
2012 (636)
2011 (611)
2010 (623)

Location

Africa (51)
Asia (1293)
Australia (180)
California (55)
Canada (30)
China (6)
Connecticut (5)
Delaware (5)
Europe (4458)
Indiana (5)
Massachusetts (72)
New Jersey (18)
New York (10)
North Carolina (15)
Northern California (29)
Pennsylvania (9)
South America (51)
Southern California (15)
Texas (6)
Washington State (5)

17,898 Results for "novartis".

Sort By

Layoffs

Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs

The closures follow Novartis’s acquisition of MorphyoSys earlier this year.

December 19, 2024
·
1 min read
·
Annalee Armstrong
Legal

Novartis Loses Appeal to Bar Entresto Generic From U.S. Market

Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.

December 5, 2024
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions

Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science

Novartis has disclosed roughly $19.4 billion in deals in the past five years. CEO Vas Narasimhan says there’s more to come.

November 21, 2024
·
2 min read
·
Annalee Armstrong
Radiopharma

Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space

The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.

November 18, 2024
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions

Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.

November 21, 2024
·
2 min read
·
Tristan Manalac
Earnings

Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.

October 29, 2024
·
2 min read
·
Tristan Manalac
Approvals

Novartis Secures First-Line CML Expansion for Scemblix, Projects $3B in Peak Sales

Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic myeloid leukemia. The expanded indication increases the eligible patient population by approximately four times, according to Novartis.

October 30, 2024
·
2 min read
·
Tristan Manalac
Approvals

Novartis Pushes Kisqali Into Earlier Stages of Breast Cancer, Nearly Doubles Eligible Patient Population

The FDA’s approval of Kisqali in combination with an aromatase inhibitor allows Novartis to target patients with earlier breast cancer who are at risk of recurrence.

September 18, 2024
·
2 min read
·
Tristan Manalac
Drug pricing

NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act.

October 21, 2024
·
2 min read
·
Tristan Manalac
Business

Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis

Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.

August 22, 2024
·
2 min read
·
Kate Goodwin

1 of 1,790

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2024 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin